Stock HAMLET B HAMLET PHARMA AB (PUBL)
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Hamlet Pharma AB (publ)

Equities

HAMLET B

SE0015661152

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hamlet: Hamlet BioPharma, the innovative pharmaceutical company, with a strong portfolio of projects, for the treatment of cancer and infections, is featured in this weekend issue of The Guardian
PU
Hamlet BioPharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
CI
Hamlet BioPharma AB Completes the First Part of A Controlled Clinical Trial in Patients with Bladder Pain Syndrome (Severe Pain in the Urinary Bladder)
CI
Hamlet BioPharma Secures Large Scale Alpha1 Peptide Production in an Agreement with Polypeptide Group
CI
Hamlet BioPharma Announces Commercial Collaborations with Top International Advisory Firms
CI
Hamlet BioPharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
Hamlet Biopharma Announces New Analyses of Clinical Data from Alpha1h Treated Patients with Bladder Cancer Detect A Strong Immune Response with Known Anti-Tumor Effects
CI
Hamlet Biopharma AB Announces Antimicrobial Peptide Therapy for Tuberculosis Infections
CI
Hamlet Biopharma's Continued Development of Brain Tumor Therapy
CI
Hamlet BioPharma Receives U.S. FDA Fast Track Designation for Alpha 1H for the Treatment of Non-Muscle Invasive Bladder Cancer
CI
Hamlet BioPharma AB Reports Earnings Results for the First Quarter Ended September 30, 2023
CI
Hamlet BioPharma AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2023
CI
Hamlet BioPharma AB Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Hamlet Pharma Announces FDA Clearance of IND Application for Alpha1H for the Treatment of Non-Muscle Invasive Bladder Cancer
CI
Hamlet Pharma Announces CEO Changes
CI
Hamlet Pharma Secures Long-Term Alpha1 Peptide Production in an Agreement with Polypeptide Group
CI
Hamlet Pharma Secures New Alpha1H Production Batch for Continued Clinical Trials
CI
Hamlet Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
CI
Hamlet BioPharma AB (NGM:HAMLET B) completed the acquisition of Selectimmune Pharma AB.
CI
Hamlet Pharma's Bladder Cancer Project Set for EU Commission's Full Funding
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HAMLET B Stock
  4. News Hamlet Pharma AB (publ)